BioVentures

BV 2010-09 - *Immunotherpy for Warts with Human Papillomavirus Type 57 (HPV 57) Antigen in Combination wtih Candida Antigen Elicits L1-specific T-cell Responses and Complete Resolution of Warts: Clinical Phase I Studies Completed*

APPLICATION:

Combining a key HPV antigen to Candida results in a faster clinical response to common wart regression. Clinical studies demonstrate safety and general clearance of warts.

SUMMARY:

It is estimated that treatment for skin warts accounts for 8.0% of the visits to U.S. dermatologists. Many warts are self-limited and regress spontaneously normally within two years however; most patients seek treatment prior to the spontaneous resolution. The many available treatments have variable results, often are painful and need to be applied to each wart individually.

The present invention is a composition comprising a HPV peptide antigen in combination with a candida antigen and a method of administering this composition to treat warts in an afflicted patient population. Using this composition and an interlesional administration, clinical studies have shown that this innovation may reduce the number of treatments necessary to resolve warts.

Studies show that this method of treatment provokes a safe immune response and clearance of HPV mediated common warts. This Immunotherapeutic method is an attractive and novel modality for treating the common wart, because the systemic immune response is effective in causing regression of distant untreated warts and prevents recurrence.

Incorporating the HPV 57 L1 peptide with Candida offers a new treatment option for common warts with enhanced immune response that promotes a faster wart regression.

Phase II clinical studies are currently being organized.

This combination appears to be superior to prior art which demonstrates the use of a single antigen (Candida, Trichophyton or Mumps) for the treatment of skin warts.